News in brief
AstraZeneca settles generic Entocort suit
Anglo-Swedish drug maker AstraZeneca has reached a settlement with Teva Pharmaceuticals over the marketing of a generic copy
of AstraZeneca’s anti-inflammatory drug Entocort (budesonide). Under the terms of the agreement, Teva will be able to sell
its budesonide in the US from 15 February 2012, subject to regulatory approval ‘or earlier in certain circumstances’. No financial
details have been disclosed.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.